The β-galactoside-α-2,3-sialyltransferase-1 ST3GAL1 catalyzes the transfer of sialic acid from cytidine monosphosphate (CMP)-sialic acid to galactose-containing substrates and is associated with cancer progression and drug resistance16,17. The gene discussed is ST3GAL1; the disease is cancer.